File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma
  • Basic View
  • Metadata View
  • XML View
TitleInhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma
 
AuthorsTam, KH1
Yang, ZF1
Lau, CK1
Lam, CT1
Pang, RWC1
Poon, RTP1
 
KeywordsChemoresistance
Chemosensitivity
HCC
mTOR
p53
RAD001
 
Issue Date2009
 
PublisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/canlet
 
CitationCancer Letters, 2009, v. 273 n. 2, p. 201-209 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.canlet.2008.08.018
 
AbstractThe present study investigated the effect of mammalian target of rapamycin (mTOR) inhibition on HCC cells in vitro and in vivo, either alone or in combination with cytotoxic agents. In vitro, HCC cell lines were exposed to RAD001, an mTOR inhibitor, either alone or in combination with cisplatin. Alone, RAD001 suppressed cell proliferation in all cell lines tested, but did not induce apoptosis. RAD001 in combination with cisplatin induced a significant increase in the number of apoptotic cells, downregulated the expression of pro-survival molecules, Bcl-2, survivin and cyclinD1, and increased the cleavage of PARP, compared to RAD001 or cisplatin alone. Transfection of p53 into the Hep3B cell line increased the sensitivity of tumor cells to cisplatin. The suppression of HCC tumor growth in vivo was enhanced by RAD001 combined with cisplatin, accompanied by a significant increase in the number of apoptotic cells in tumor tissues. This study demonstrates that inhibition of mTOR suppresses tumor growth and sensitizes tumor cells to chemocytotoxic agents. © 2008 Elsevier Ireland Ltd. All rights reserved.
 
ISSN0304-3835
2013 Impact Factor: 5.016
 
DOIhttp://dx.doi.org/10.1016/j.canlet.2008.08.018
 
ISI Accession Number IDWOS:000262582100003
Funding AgencyGrant Number
Seed Funding Program for Basic Research 2006
Sun Chieh Yeh Research Foundation
Funding Information:

The study was supported by the Seed Funding Program for Basic Research 2006 and Sun Chieh Yeh Research Foundation for Hepatobiliary and Pancreatic Surgery of the University of Hong Kong.

 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorTam, KH
 
dc.contributor.authorYang, ZF
 
dc.contributor.authorLau, CK
 
dc.contributor.authorLam, CT
 
dc.contributor.authorPang, RWC
 
dc.contributor.authorPoon, RTP
 
dc.date.accessioned2010-05-31T03:44:03Z
 
dc.date.available2010-05-31T03:44:03Z
 
dc.date.issued2009
 
dc.description.abstractThe present study investigated the effect of mammalian target of rapamycin (mTOR) inhibition on HCC cells in vitro and in vivo, either alone or in combination with cytotoxic agents. In vitro, HCC cell lines were exposed to RAD001, an mTOR inhibitor, either alone or in combination with cisplatin. Alone, RAD001 suppressed cell proliferation in all cell lines tested, but did not induce apoptosis. RAD001 in combination with cisplatin induced a significant increase in the number of apoptotic cells, downregulated the expression of pro-survival molecules, Bcl-2, survivin and cyclinD1, and increased the cleavage of PARP, compared to RAD001 or cisplatin alone. Transfection of p53 into the Hep3B cell line increased the sensitivity of tumor cells to cisplatin. The suppression of HCC tumor growth in vivo was enhanced by RAD001 combined with cisplatin, accompanied by a significant increase in the number of apoptotic cells in tumor tissues. This study demonstrates that inhibition of mTOR suppresses tumor growth and sensitizes tumor cells to chemocytotoxic agents. © 2008 Elsevier Ireland Ltd. All rights reserved.
 
dc.description.naturelink_to_subscribed_fulltext
 
dc.identifier.citationCancer Letters, 2009, v. 273 n. 2, p. 201-209 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.canlet.2008.08.018
 
dc.identifier.doihttp://dx.doi.org/10.1016/j.canlet.2008.08.018
 
dc.identifier.epage209
 
dc.identifier.hkuros154431
 
dc.identifier.isiWOS:000262582100003
Funding AgencyGrant Number
Seed Funding Program for Basic Research 2006
Sun Chieh Yeh Research Foundation
Funding Information:

The study was supported by the Seed Funding Program for Basic Research 2006 and Sun Chieh Yeh Research Foundation for Hepatobiliary and Pancreatic Surgery of the University of Hong Kong.

 
dc.identifier.issn0304-3835
2013 Impact Factor: 5.016
 
dc.identifier.issue2
 
dc.identifier.openurl
 
dc.identifier.pmid18824293
 
dc.identifier.scopuseid_2-s2.0-57349106607
 
dc.identifier.spage201
 
dc.identifier.urihttp://hdl.handle.net/10722/59161
 
dc.identifier.volume273
 
dc.languageeng
 
dc.publisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/canlet
 
dc.publisher.placeIreland
 
dc.relation.ispartofCancer Letters
 
dc.relation.referencesReferences in Scopus
 
dc.rightsCancer Letters. Copyright © Elsevier Ireland Ltd.
 
dc.subjectChemoresistance
 
dc.subjectChemosensitivity
 
dc.subjectHCC
 
dc.subjectmTOR
 
dc.subjectp53
 
dc.subjectRAD001
 
dc.titleInhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Tam, KH</contributor.author>
<contributor.author>Yang, ZF</contributor.author>
<contributor.author>Lau, CK</contributor.author>
<contributor.author>Lam, CT</contributor.author>
<contributor.author>Pang, RWC</contributor.author>
<contributor.author>Poon, RTP</contributor.author>
<date.accessioned>2010-05-31T03:44:03Z</date.accessioned>
<date.available>2010-05-31T03:44:03Z</date.available>
<date.issued>2009</date.issued>
<identifier.citation>Cancer Letters, 2009, v. 273 n. 2, p. 201-209</identifier.citation>
<identifier.issn>0304-3835</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/59161</identifier.uri>
<description.abstract>The present study investigated the effect of mammalian target of rapamycin (mTOR) inhibition on HCC cells in vitro and in vivo, either alone or in combination with cytotoxic agents. In vitro, HCC cell lines were exposed to RAD001, an mTOR inhibitor, either alone or in combination with cisplatin. Alone, RAD001 suppressed cell proliferation in all cell lines tested, but did not induce apoptosis. RAD001 in combination with cisplatin induced a significant increase in the number of apoptotic cells, downregulated the expression of pro-survival molecules, Bcl-2, survivin and cyclinD1, and increased the cleavage of PARP, compared to RAD001 or cisplatin alone. Transfection of p53 into the Hep3B cell line increased the sensitivity of tumor cells to cisplatin. The suppression of HCC tumor growth in vivo was enhanced by RAD001 combined with cisplatin, accompanied by a significant increase in the number of apoptotic cells in tumor tissues. This study demonstrates that inhibition of mTOR suppresses tumor growth and sensitizes tumor cells to chemocytotoxic agents. &#169; 2008 Elsevier Ireland Ltd. All rights reserved.</description.abstract>
<language>eng</language>
<publisher>Elsevier Ireland Ltd. The Journal&apos;s web site is located at http://www.elsevier.com/locate/canlet</publisher>
<relation.ispartof>Cancer Letters</relation.ispartof>
<rights>Cancer Letters. Copyright &#169; Elsevier Ireland Ltd.</rights>
<subject>Chemoresistance</subject>
<subject>Chemosensitivity</subject>
<subject>HCC</subject>
<subject>mTOR</subject>
<subject>p53</subject>
<subject>RAD001</subject>
<title>Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0304-3835&amp;volume=273&amp;issue=2&amp;spage=201&amp;epage=209&amp;date=2009&amp;atitle=Inhibition+of+mTOR+enhances+chemosensitivity+in+hepatocellular+carcinoma</identifier.openurl>
<description.nature>link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1016/j.canlet.2008.08.018</identifier.doi>
<identifier.pmid>18824293</identifier.pmid>
<identifier.scopus>eid_2-s2.0-57349106607</identifier.scopus>
<identifier.hkuros>154431</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-57349106607&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>273</identifier.volume>
<identifier.issue>2</identifier.issue>
<identifier.spage>201</identifier.spage>
<identifier.epage>209</identifier.epage>
<identifier.isi>WOS:000262582100003</identifier.isi>
<publisher.place>Ireland</publisher.place>
</item>
Author Affiliations
  1. The University of Hong Kong